SCHEMBL24656368

SCHEMBL24656368

CC(C)(C)c1ccnc2c1CCOC2

nearest known ligand 0.32

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
WNT3A P56704 2/20 0.32
TNKS2 Q9H2K2 2/20 0.32
TNKS O95271 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26818254 0.87 WNT3A (0.36) WNT3ATNKS2
SCHEMBL25527883 0.77 WNT3A (0.33) WNT3ATNKS2TNKS
SCHEMBL22387691 0.75 NOS3 (0.36)
SCHEMBL22019768 0.75 GRM4 (0.36)
SCHEMBL20897927 0.74 WNT3A (0.33) WNT3ATNKS2TNKS
SCHEMBL31133463 0.74 WNT3A (0.33) WNT3ATNKS2TNKS
SCHEMBL14289084 0.72
SCHEMBL21818659 0.71 HSD11B1 (0.36) WNT3ATNKS2TNKS
SCHEMBL31133375 0.71 HSD11B1 (0.36) WNT3ATNKS2TNKS
SCHEMBL12395081 0.70 ATM (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11820766-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-11-21 US disclosed
US-20230145249-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2023-05-11 US disclosed
US-20220332713-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2022-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220332713-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP WNT3A 3874/4885TNKS2 3411/4885TNKS 3262/4885
US-20230145249-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP WNT3A 3874/4885TNKS2 3411/4885TNKS 3262/4885
US-11820766-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP WNT3A 3874/4885TNKS2 3411/4885TNKS 3262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.